相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study
Linghui Zhou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Rene-Olivier Casasnovas et al.
LANCET ONCOLOGY (2019)
Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry
Irene Biasoli et al.
HEMATOLOGICAL ONCOLOGY (2018)
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry
Irene Biasoli et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. A. Eichenauer et al.
ANNALS OF ONCOLOGY (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
David J. Straus et al.
BLOOD (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
NCCN Guidelines® Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines
Richard T. Hoppe et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
Richard A. Anderson et al.
LANCET ONCOLOGY (2018)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Peter Borchmann et al.
LANCET (2017)
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Boris Boell et al.
BLOOD (2016)
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Patrice Carde et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Global Health Equity: Cancer Care Outcome Disparities in High-, Middle-, and Low-Income Countries
Jonas A. de Souza et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana
Jason A. Efstathiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
John M. Timmerman et al.
BLOOD (2016)
Defining the diagnostic divide: an analysis of registered radiological equipment resources in a low-income African country
Patrick Sitati Ngoya et al.
PAN AFRICAN MEDICAL JOURNAL (2016)
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Karolin Behringer et al.
LANCET (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution
Rahul Narayan Maddi et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2015)
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial
N. Mounier et al.
ANNALS OF ONCOLOGY (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin
Massimiliano Salati et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2014)
Hodgkin's lymphoma mortality in the Americas, 1997-2008: Achievements and persistent inadequacies
Liliane Chatenoud et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
Alison J. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group
Diana Wongso et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis
Nicole Skoetz et al.
LANCET ONCOLOGY (2013)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert et al.
LANCET (2012)
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Ralph M. Meyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Management of fertility in patients treated for Hodgkin's lymphoma
Stephanie Harel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Simonetta Viviani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review
Christine Herbst et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519)
Peter W. M. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CURRENT CONCEPTS Early-Stage Hodgkin's Lymphoma
James O. Armitage
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Andreas Engert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
Andreas Engert et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
Peter J. Hoskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Standard therapy of advanced Hodgkin lymphoma
J. Kuruvilla
Hematology-American Society of Hematology Education Program (2009)
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the lymphoma working party of the European group for blood and marrow transplantation
Anna Sureda et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review
Ginna G. Laport
LEUKEMIA & LYMPHOMA (2008)
Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma:: Final results of the GHSG HD7 trial
Andreas Engert et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors
E. Boleti et al.
ANNALS OF ONCOLOGY (2007)
Breast cancer in limited-resource countries: An overview of the breast health global initiative 2005 guidelines
BO Anderson et al.
BREAST JOURNAL (2006)
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
WG Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma:: A retrospective analysis from the German Hodgkin Lymphoma Study Group
A Josting et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
DJ Straus et al.
BLOOD (2004)
Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?
S Laskar et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Involved-field radiotherapy for advanced Hodgkin's lymphoma
BMP Aleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours
JM O'Sullivan et al.
ANNALS OF ONCOLOGY (2003)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Gemcitabine in the treatment of refractory Hodgkins's disease: Results of a multicenter phase II study
A Santoro et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
